General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Quast, Sandra Annika ^a,b   Berger, Anja ^a   Buttstädt, Nicole ^c   Friebel, Kristin ^c   Schönherr, Roland ^c   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCA3.1; PROTEIN BAX; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; RECEPTOR UPREGULATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; POTASSIUM CHANNEL BLOCKERS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84862491784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039290     Document Type: Article

References (53)

1. Garbe C, Leiter U, (2009) Melanoma epidemiology and trends. Clin.Dermatol. 27: 3-9.
2. Eberle J, Kurbanov B M, Hossini A M, Trefzer U, Fecker L F, (2007) Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist.Updat. 10: 218-234.
3. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, et al. (2010) TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. Journal of Molecular Medicine-Jmm 88: 729-740.
4. Degli-Esposti MA SPWHWJHCDRGRSC, (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J.Exp.Med 186: 1165-1170.
5. Degli-Esposti MA, Dougall W C, Smolak P J, Waugh J Y, Smith C A, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 813-820.
6. Koschny R, Walczak H, Ganten T M, (2007) The promise of TRAIL- potential and risks of a novel anticancer therapy. Journal of Molecular Medicine-Jmm 85: 923-935.
7. Kurbanov BM, Geilen C C, Fecker L F, Orfanos C E, Eberle J, (2005) Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J.Invest Dermatol. 125: 1010-1019.
8. Kurbanov BM, Fecker L F, Geilen C C, Sterry W, Eberle J, (2007) Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 26: 3364-3377.
9. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P, (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clinical Cancer Research 12: 1355-1364.
10. Tait SWG, Green D R, (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nature Reviews Molecular Cell Biology 11: 621-632.
11. Mellier G, Huang S, Shenoy K, Pervaiz S, (2010) TRAILing death in cancer. Mol.Aspects Med. 31: 93-112.
12. Chipuk JE, Moldoveanu T, Llambi F, Parsons M J, Green D R, (2010) The BCL-2 Family Reunion. Molecular Cell 37: 299-310.
13. Du CY, Fang M, Li Y C, Li L, Wang X D, (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42.
14. Fischer U, Janicke R U, Schulze-Osthoff K, (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death and Differentiation 10: 76-100.
15. Norberg E, Orrenius S, Zhivotovsky B, (2010) Mitochondrial regulation of cell death: Processing of apoptosis-inducing factor (AIF). Biochemical and Biophysical Research Communications 396: 95-100.
16. Riedl SJ, Shi Y, (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat.Rev.Mol.Cell Biol. 5: 897-907.
17. Deveraux QL, Reed T C, (1999) IAP family proteins- suppressors of apoptosis. Genes & Development 13: 239-252.
18. Chai JJ, Du C Y, Wu J W, Kyin S, Wang X D, et al. (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406: 855-862.
19. Wickenden A, (2002) K(+) channels as therapeutic drug targets. Pharmacol.Ther. 94: 157-182.
20. Wulff H, Miller M J, Hansel W, Grissmer S, Cahalan M D, et al. (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc.Natl.Acad.Sci.U.S.A 97: 8151-8156.
21. Schonherr R, (2005) Clinical relevance of ion channels for diagnosis and therapy of cancer. Journal of Membrane Biology 205: 175-184.
22. Elliott JI, Higgins C F, (2003) IKCa1 activity is required for cell shrinkage, phosphatidylserine translocation and death in T lymphocyte apoptosis. EMBO Rep. 4: 189-194.
23. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, et al. (2003) Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am.J.Physiol Cell Physiol 285: C1553-C1560.
24. Raisova M, Hossini A, Riebeling C, Wieder T, Daniel P, et al. (2001) Apoptosis resistance in human melanoma cells. Journal of Investigative Dermatology 117: 168.
25. Gillissen B, Wendt J, Richter A, Richter A, Muer A, et al. (2010) Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J.Cell Biol. 188: 851-862.
26. Eberle J, Fecker L F, Hossini A M, Wieder T, Daniel P T, et al. (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22: 9131-9141.
27. Schwab A, Nechyporuk-Zloy V, Gassner B, Schulz C, Kessler W, et al. (2012) Dynamic redistribution of calcium sensitive potassium channels (hKCa3.1) in migrating cells. Journal of Cellular Physiology 227: 686-696.
28. Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, et al. (2002) Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J.Membr.Biol. 188: 137-149.
29. Riccardi C, Nicoletti I, (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat.Protoc. 1: 1458-1461.
30. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 58: 621-681.
31. Silver N, Best S, Jiang J, Thein S L, (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. Bmc Molecular Biology 7.
32. Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, et al. (1999) Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nature Medicine 5: 157-163.
33. Ashkenazi A, (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer 2: 420-430.
34. Herbst RS, Eckhardt S G, Kurzrock R, Ebbinghaus S, O'Dwyer P J, et al. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J.Clin.Oncol. 28: 2839-2846.
35. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, et al. (2011) Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 29: 4442-4451.
36. Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, et al. (2006) Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Research 66: 8520-8528.
37. Ivanov VN, Partridge M A, Johnson G E, Huang S X, Zhou H, et al. (2008) Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp.Cell Res. 314: 1163-1176.
38. Jiang CC, Chen L H, Gillespie S, Kiejda K A, Mhaidat N, et al. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67: 5880-5888.
39. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H, et al. (2010) Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene.
40. Berger A, Quast S A, Plotz M, Hein M, Kunz M, et al. (2010) Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative-Enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem.Pharmacol.
41. Chou CC, Lunn C A, Murgolo N J, (2008) KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert.Rev.Mol.Diagn. 8: 179-187.
42. Lee EL, Hasegawa Y, Shimizu T, Okada Y, (2008) IK1 channel activity contributes to cisplatin sensitivity of human epidermoid cancer cells. Am.J.Physiol Cell Physiol 294: C1398-C1406.
43. Schwab A, Reinhardt J, Schneider S W, Gassner B, Schuricht B, (1999) K+ channel-dependent migration of Fibroblasts and human melanoma cells. Cellular Physiology and Biochemistry 9: 126-132.
44. Schmidt J, Friebel K, Schonherr R, Coppolino M G, Bosserhoff A K, (2010) Migration-associated secretion of melanoma inhibitory activity at the cell rear is supported by KCa3.1 potassium channels. Cell Res. 20: 1224-1238.
45. Szabo I, Bock J, Jekle A, Soddemann M, Adams C, et al. (2005) A novel potassium channel in lymphocyte mitochondria. Journal of Biological Chemistry 280: 12790-12798.
46. Sassi N, De Marchi U, Fioretti B, Biasutto L, Gulbins E, et al. (2010) An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca(2+)-activated K(+) channel mtK(Ca)3.1. Biochim.Biophys.Acta 1797: 1260-1267.
47. Szabo I, Bock J, Grassme H, Soddemann M, Wilker B, et al. (2008) Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 105: 14861-14866.
48. Garlid KD, Paucek P, (2003) Mitochondrial potassium transport: the K+ cycle. Biochimica et Biophysica Acta-Bioenergetics 1606: 23-41.
49. Huttemann M, Pecina P, Rainbolt M, Sanderson T H, Kagan V E, et al. (2011) The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis. Mitochondrion 11: 369-381.
50. Fulda S, Vucic D, (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat.Rev.Drug Discov. 11: 109-124.
51. Vogler M, Walczak H, Stadel D, Haas T L, Genze F, et al. (2009) Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research 69: 2425-2434.
52. Zhang XD, Zhang X Y, Gray C P, Nguyen T, Hersey P, (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61: 7339-7348.
53. Ataga KI, Stocker J, (2009) Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opinion on Investigational Drugs 18: 231-239.